Intravenous Immunoglobulin (IVIg) - 2015 Global Strategic Business Report: Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth

News provided by

Mar 20, 2015, 07:43 ET

DUBLIN, Mar. 19, 2015 /PRNewswire/ --Research and Markets

(http://www.researchandmarkets.com/research/kxb3sr/intravenous) has announced the addition of the "Intravenous Immunoglobulin (IVIg) - Global Strategic Business Report" report to their offering.

This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million and in Kilograms. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World.

Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 25 companies including many key and niche players such as:

Baxter International, Inc. (US)
Beijing Tiantan Biological Products Co., Ltd (China)
Bharat Serums and Vaccines Limited (India)
Biotest AG (Germany)
China Biologic Products, Inc (China)
Guizhou Taibang Biological Products Co., Ltd (China)
CSL Limited (Australia)
CSL Behring LLC (US)
Grifols, S.A (Spain)
Hualan Biological Engineering Inc. (China)
Kedrion S.p.A. (Italy)
LFB Group (France)
Octapharma AG (Switzerland)
OMRIX Biopharmaceuticals Ltd (Israel)
Shanghai RAAS Blood Products Co., Ltd. (China)
Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd (China)

Key Topics Covered:

1. INDUSTRY OVERVIEW

Intravenous Immunoglobulin - A Proliferating Biologic
List of FDA-Approved and Off-Label Uses of Intravenous Immunoglobulin Therapy
Regional Market Perspective
Growth Drivers and Market Challenges
Competitive Scenario
IVIg Products Offered by Global Leading Players (2013)

2. MARKET TRENDS

Increasing Awareness of Primary Immunodeficiency Disease to Drive IVIg Market
Subcutaneous IG Formulations Gain Therapeutic Foothold
Hyperimmune Globulin - Taking IVIg Therapy a Step Ahead
IVIg Treatment for Alzheimer's Hindered by Unsuccessful Clinical Trials
Synthetic Replacements to IVIg Therapy
IVIg Therapy - Home-based vs. Outpatient Settings
IVIg Prices to Remain Strong both in the US and Outside the US
Per Capita Consumption Rate Varies Across Countries
Baxter's Gammagard, the Leading Immunoglobulin Product in the US
Strong Demand from Major Indications and Pipeline SCIg Products to Fuel Growth
Favorable Reimbursement and High Usage make US the Largest Consumer of Immunoglobulins Worldwide
Growing Adoption of Screening Programs to Reduce Usage of Immunoglobulins in the Treatment of SCID
Aging Global Population: Major Opportunity Indicator
Improving Healthcare Expenditure to Foster Growth

3. PLASMA PROTEINS - AN OVERVIEW

Plasma Market Witnesses Surging Demand
Regulations Exercise a Tight Rein over Plasma Therapy & Immunoglobulins

4. THERAPY OVERVIEW

Immunoglobulins Overview
IVIg and SCIg: A Face-off!
Cost of Product and Treatment
Side-Effects
Frequency of Treatment
Safety Considerations
Patient Response to Treatment Varies
Site of Care
IVIg Therapy Introduction
Intravenous Immunoglobulin
Mechanism of IVIg Action
IVIg Dosage and Treatment Response Time
Common IVIg Intravenous Dosing Recommendations by Indication
Complications and Side Effects of Using IVIg
Precautions to be Undertaken
Intravenous Immunoglobulin - Indications
FDA Approved Indications for IVIg
Off-Label Usage of IVIg
Select Off-Label Indications for IVIg
Applications by Medical Specialty
Neurology
Hematology
Immunology
Dermatology
Nephrology, Rheumatology, Ophthalmology, and Other Diseases

5. REGULATORY APPROVALS

CSL Behring Obtains EC Marketing Approval for Privigen® for CIDP Patients
CSL Behring Obtains FDA Approval for Privigen® to Treat PID and ITP
Biotest Pharmaceuticals Obtains FDA Approval for BIVGAM IVIg
Baxter Obtains EC Marketing Approval for HyQvia
Green Cross Receives Approval to Commence Phase III Clinical Trials
Baxter Bags FDA Approval for GAMMAGARD LIQUID to Treat MMN

6. PRODUCT INNOVATIONS/INTRODUCTIONS

Octapharma Canada Introduces Octagam®10% in Canada
Biotest Introduces BIVIgAM in the US

7. RECENT INDUSTRY ACTIVITY

Emergent BioSolutions Acquires Cangene
CMS Begins Evaluation of Payment for In-home IVIG Administration
AxelaCare Acquires SCP Specialty Infusion
Pfizer to License Gliknik's GL-2045
Octapharma Completes Phase II Clinical Trial of Octagam 10% for Alzheimer's
Grifols International Establishes New IVIg Purification Facility in Los Angeles
Sorrento Therapeutics Secures Global Rights for Using G-MAB® Antibody Library Technology to Produce rIVIg
Momenta Pharmaceuticals Acquires Sialic Switch Assets of Virdante Pharmaceuticals
Grifols' AMBAR Study Integrates Therapeutic Plasmapheresis with Alternating Infusion of IVIg and Albumin for Treatment of Alzheimer's Disease
Biotest Publishes Clinical Trial Data Related to New Investigational IVIg Product

8. FOCUS ON SELECT PLAYERS

9. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 25 (including Divisions/Subsidiaries - 30)